Home / Resources / Videos / ADA 2017 / Ronald Swerdloff Part 4, Testosterone Levels

Ronald Swerdloff Part 4, Testosterone Levels

In part 4 of this Exclusive Interview, Dr. Ronald Swerdloff explains the range of normal testosterone levels in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

Ronald Swerdloff, MD is a professor of medicine at David Geffen School of Medicine at UCLA, the chief of division of endocrinology and metabolism at the Harbor UCLA Medical Center, and the senior investigator at the LA Biomedical Research Institute.

Transcript of this video segment:

Steve: So, you do a blood test, and they find out your level of testosterone. There is a big range of what normal is. What is normal?  What is considered normal? And as we get older that number obviously changes.

Dr. Swerdloff:  The question you’re really asking is what is your target? You start with low level of testosterone, everybody agrees it’s low, it’s been replicated, you see a low level and then you treat. So what do you aim for?  What blood level do you aim for?  We do not know for certain of that answer.  We aim for levels in the reference range, in the population range, we sort of aim for the middle of that.  Maybe for the older people we might aim for a little bit lower level.  But, we don’t know for certain exactly what levels we would like to retain.

Steve:  What are some specific numbers of that area?

Dr. Swerdloff:  In the United States we’ve heard of things in nanograms per deciliter. The reference range, the population range, is somewhere about 280 to about 1000. And that is a big range. What that means is that different people respond to the testosterone, to the hormone in the blood, differently in order to keep the level that their system thinks is the ideal level. That’s the concept that we have. You can’t really tell by looking at somebody who has the value of 400 and compare them to a person with a value of 800 – they look more or less the same. That means that there must be a difference in sensitivity at the end organ that responds to the hormone, that it greater or lesser but both of them one way or another get the same net effect when you look at their clinical manifestations.  That is sort of the idea that we have at present time.

Return to the main page.